Latest News

Recent FDA actions include updates in HIV, influenza, narcolepsy, type 2 diabetes, and RSV prevention in high-risk children.

FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.

The proportion of US women aged 21 to 29 years who have never received cervical cancer screening more than doubled between 2005 and 2023, according to new data.

Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.

Physical activity was associated with up to 22% lower mortality and 19% lower stroke risk in adults with and without atrial fibrillation in a large Norwegian cohort study.

FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.

FDA authorized Abbott’s Libre Duo 10 Day system, the first wearable device to continuously monitor both glucose and ketones.

Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.